Invesco Ltd. Has $77.13 Million Stock Holdings in BioLife Solutions, Inc. $BLFS

Invesco Ltd. grew its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS) by 0.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,580,778 shares of the medical equipment provider’s stock after acquiring an additional 29,724 shares during the period. Invesco Ltd. owned 0.07% of BioLife Solutions worth $77,130,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. T. Rowe Price Investment Management Inc. bought a new stake in BioLife Solutions in the first quarter worth $30,789,000. Royal Bank of Canada lifted its position in shares of BioLife Solutions by 762.8% in the first quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider’s stock worth $15,948,000 after buying an additional 617,320 shares during the last quarter. Mutual of America Capital Management LLC boosted its stake in shares of BioLife Solutions by 22.2% during the 2nd quarter. Mutual of America Capital Management LLC now owns 638,373 shares of the medical equipment provider’s stock worth $13,751,000 after acquiring an additional 115,963 shares in the last quarter. TD Asset Management Inc increased its holdings in shares of BioLife Solutions by 271.7% during the 2nd quarter. TD Asset Management Inc now owns 144,290 shares of the medical equipment provider’s stock valued at $3,108,000 after acquiring an additional 105,470 shares during the last quarter. Finally, Raymond James Financial Inc. increased its holdings in shares of BioLife Solutions by 12.7% during the 1st quarter. Raymond James Financial Inc. now owns 897,421 shares of the medical equipment provider’s stock valued at $20,497,000 after acquiring an additional 101,423 shares during the last quarter. Institutional investors own 93.24% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on BLFS shares. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of BioLife Solutions in a report on Monday, November 24th. Zacks Research lowered shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Monday. Finally, Wall Street Zen cut shares of BioLife Solutions from a “buy” rating to a “hold” rating in a report on Sunday, November 30th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.20.

Insider Activity

In related news, CEO Greef Roderick De sold 37,795 shares of the company’s stock in a transaction on Wednesday, October 22nd. The stock was sold at an average price of $27.30, for a total value of $1,031,803.50. Following the completion of the transaction, the chief executive officer directly owned 489,998 shares in the company, valued at approximately $13,376,945.40. This represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Casdin Partners Master Fund, L sold 750,000 shares of the firm’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $28.55, for a total value of $21,412,500.00. Following the completion of the transaction, the insider directly owned 5,957,165 shares of the company’s stock, valued at approximately $170,077,060.75. This trade represents a 11.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 932,891 shares of company stock valued at $26,193,244. Corporate insiders own 2.20% of the company’s stock.

BioLife Solutions Stock Performance

NASDAQ:BLFS opened at $24.77 on Thursday. The firm’s 50-day moving average is $26.52 and its 200-day moving average is $24.43. BioLife Solutions, Inc. has a 52-week low of $19.10 and a 52-week high of $29.62. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -353.81 and a beta of 1.93.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.